More Retreatment Options Needed for Advanced Breast Cancer Patients w/ Breast Cancer Foundation's Adele Gautier: August 28, 2023

Last Wednesday, Pharmac confirmed it would be replacing treatment Herceptin (brand name for the drug Trastuzumab) with Herzuma, another version of the drug which is equally as effective but at a lower cost. Pharmac has decided not to provide more retreatment opportunities for patients with advanced HER2-positive breast cancer, but Breast Cancer Foundation New Zealand is urging them to reconsider.

Rosetta spoke to Adele Gautier, Research and Strategic Programmes Manager for BCFNZ about the decision, and what more needs to be done to increase retreatment options in Aotearoa.